Valeria Lifke

USPTO Granted Patents = 13 (Patent Applications = 22)

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 67(Granted Patents)

Company Filing History:

9 out of 4,948

Hoffmann-la Roche Inc.

Bernd Mueller-beckmann

patent

4. 1 out of 832,891

Other

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12391757 - Bispecific antibodies specific for PD1 and TIM3 (2025-08-19),

2. 11130810 - Bispecific antibodies specific for PD1 and TIM3 (2021-09-28),

3. 10287352 - Bispecific antibodies specific for PD1 and TIM3 (2019-05-14),

4. 10196456 - Anti-HER3 antibodies and uses thereof (2019-02-05),

5. 9611331 - Anti-HER3 antibodies and uses thereof (2017-04-04),

6. 9399670 - Method for obtaining immunoglobulin encoding nucleic acid (2016-07-26),

7. 9339560 - Method for determining the anti-tumor efficacy of monoclonal antibodies (2016-05-17),

8. 9309319 - Antibodies against human IL33R and uses thereof (2016-04-12),

9. 9290567 - Use of an anti-Tau pS422 antibody for the treatment of brain diseases (2016-03-22),

10. 8884096 - Method for the production of antibodies (2014-11-11),

11. 8859737 - Anti-HER3 antibodies and uses thereof (2014-10-14),

12. 8785153 - Antibodies against human IL33R and uses thereof (2014-07-22),

13. 8609097 - Use of an anti-Tau pS422 antibody for the treatment of brain diseases (2013-12-17),

Title: Valeria Lifke: Innovator in Bispecific Antibodies

Introduction

Valeria Lifke is a prominent inventor based in Penzberg, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. With a total of 13 patents to her name, her work has the potential to impact therapeutic approaches in various medical conditions.

Latest Patents

One of her latest inventions involves bispecific antibodies that are specific for PD1 and TIM3. This invention relates to antibodies that comprise a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3. Notably, the bispecific antibody binds to TIM3 with a lower binding affinity compared to its binding to PD1. The invention also encompasses methods for producing these molecules and their applications in medical treatments.

Career Highlights

Throughout her career, Valeria has worked with notable companies in the biotechnology sector, including Hoffmann-La Roche Inc. and Roche Glycart AG. Her experience in these organizations has allowed her to refine her expertise in antibody development and therapeutic applications.

Collaborations

Valeria has collaborated with esteemed colleagues such as Hans-Willi Krell and Georg Fertig. These partnerships have contributed to her innovative research and the advancement of her inventions.

Conclusion

Valeria Lifke's work in bispecific antibodies showcases her dedication to advancing medical science through innovation. Her contributions are paving the way for new therapeutic strategies in the treatment of diseases.

This text is generated by artificial intelligence and may not be accurate.